http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
이산희,Ga Won Yim,김상운,김성훈,김재욱,김영태,이대우 대한부인종양학회 2008 Journal of Gynecologic Oncology Vol.19 No.4
Objective: The aim of this study was to compare operative feasibility and surgical outcome of the modified Cherney incision and vertical midline incision in patients undergoing radical hysterectomy and pelvic lymphadenectomy. Methods: Between March 2005 and December 2007, retrospective data of 78 patients (n=17; modified Cherney incision, n=61; vertical midline incision) with early stage cervical cancer who received radical hysterectomy and pelvic lymphadenectomy were reviewed. Results: Baseline characteristics of patients who underwent modified Cherney incision and vertical midline incision were similar except for age (mean±SD: 32.3±3.4 yr vs. 52.5±8.4 yr, p<0.001). Patients who received modified Cherney incision had earlier initiation of soft diet (mean±SD: 46.5±19.5 hr vs. 56.4±25.4 hr, p<0.016) and shorter hospital stay compared to those who received vertical midline incision (mean±SD: 18.0±4.8 days vs. 21.7±3.7 days, p<0.042). There was no difference in the number of dissected pelvic lymph nodes, hemoglobin change, postoperative pain, postoperative ileus, Foley indwelling duration, and perioperative complications. Conclusion: Excluding the selection bias for age, there was no significant difference of the clinical outcome between the modified Cherney incision group and the vertical midline incision group. Modified Cherney incision can be cosmetically performed in young age women obtaining equal number of lymph nodes without increased operative morbidity compared to vertical midline incision.
기계학습(Machine Learning)을 이용한 웨어러블 디바이스의 생체신호와 월경관련 증상에 따른 월경주기 예측
이산희,안정환,박선화,임승주,유희성 대한산부인과학회 2022 대한산부인과학회 학술대회 Vol.108 No.-
Objective: 본 연구는 심전도 및 호흡수를 측정할 수 있는 웨어러블 디바이스(HiCardiⓇ)와 개인의 월경 관련 증상을 관리할 수 있는 어플리케이션을 개발하여, 두 기기로부터 얻은 데이터가 월경주기를 예측할 수 있는지 기계학습을 통해 알아보고자 하였다. Methods: 본 연구는 19세 이상 45세 미만 성인기 여성 18명을 대상으로 2개월간 자료를 수집하였다. 독립변수인 심전도 데이터는 웨어러블 디바이스를 통해 수집하였고, 월경관련 증상은 자체개발한 월경 어플리케이션을 활용하였으며, 종속변수는 범주형 변수로서 월경여부 응답자료를 사용하였다. 본 연구는 R studio를 사용하여, 수집한 데이터를 바탕으로 월경주기 예측력을 도출하고자 기계학습의 일환으로서 랜덤포레스트를 적용하였다. Results: 측정된 심전도 데이터를 랜덤포레스트 모형에 투입한 결과, 약 77%(AUC=0.7627)의 정확도로 월경여부를 예측하는 것으로 나타났다. 또한, 수집된 월경관련 정신건강 변수를 분석한 결과, 약 88%(AUC=0.8839)의 정확도로 월경여부를 예측하는 것으로 나타났다. 본 연구 결과를 통해 심전도뿐만 아니라 정신건강 변수도 포함하여 분석하였을 때 월경주기 예측력이 향상됨을 확인하였다. 따라서, 다양한 요인으로부터 영향을 받는 여성의 월경주기 예측을 위해서는 다각적 측면에서 영향을 미치는 변수를 고려할 필요가 있음을 시사한다. Conclusion: 본 연구는 향후 연령대별, 질환군별 정확한 월경주기 예측 알고리즘을 개발 연구를 위한 근거를 마련하였다는 점에서 의의가 있다. 향후 월경장애 진단 및 치료 알고리즘에 따른 통합적인 월경장애 솔루션 제공이 실현되기를 기대한다.
마음읽기 중재가 자폐범주성장애 아동의 이야기 회상 산출에 미치는 효과
이산희(San-Hui Lee),서경희(Kyung-Hee Sehr),정한진(Han-Jin Jeong),유진(Jin Yu),이효진(Hyo-Jin Lee) 한국의료정보교육협회 2018 보건의료생명과학논문지 Vol.6 No.2
본 논문에서는 마음읽기 중재가 ASD 아동의 이야기 회상산출 능력에 미치는 효과를 알아보고자 하였다. 연구는 행동간 중다 기초선 설계로 이루어졌으며 기초선 1회기, 중재 8회기, 중재철회 1회기로 진행되었다. 연구 결과, 마음읽기 중재를 사용하였을 때 대상아동의 이야기 회상산출 능력이 증가되었다. 이를 통해 마음읽기 중재가 ASD 아동의 이야기 회상산출에 긍정적인 효과가 있음을 확인할 수 있었다. The purpose of this study was to investigate the effect of mind reading intervention on the recall of ASD children. This study was designed as a single case study (A-B-A). As a result of the study, when the mind reading intervention was used, the ability of the target child to recall the story was increased. This suggests that the mind reading intervention has a positive effect on the story recall of ASD children.
최선민,이산희,박상효,박선화,박채원,기재홍 연세대학교의과대학 2021 Yonsei medical journal Vol.62 No.11
Purpose: Indocyanine green (ICG) is a promising agent for intraoperative visualization of tumor tissues and sentinel lymph nodes in early-stage gynecological cancer. However, it has some limitations, including a short half-life and poor solubility in aqueous solutions. This study aimed to enhance the efficacy of near-infrared (NIR) fluorescence imaging by overcoming the shortcomings of ICG using a nano-drug delivery system and improve target specificity in cervical cancer. Materials and Methods: ICG and poly(lactic-co-glycolic acid) (PLGA) conjugated with polyethylenimine (PEI) were assembled to enhance stability. Hyaluronic acid (HA) was coated on PEI-PLGA-ICG nanoparticles to target CD44-positive cancer cells. The manufactured HA-ICG-PLGA nanoparticles (HINPs) were evaluated in vitro and in vivo on cervical cancer cells (SiHa; CD44+) and human dermal cells (ccd986sk; CD44-), respectively, using NIR imaging to compare intracellular uptake and to quantify the fluorescence intensities of cells and tumors. Results: HINPs were confirmed to have a mean size of 200 nm and a zeta-potential of 33 mV using dynamic light scattering. The stability of the HINPs was confirmed at pH 5.0–8.0. Cytotoxicity assays, intracellular uptake assays, and cervical cancer xenograft models revealed that, compared to free ICG, the HINPs had significantly higher internalization by cervical cancer cells than normal cells (p<0.001) and significantly higher accumulation in tumors (p<0.001) via CD44 receptor-mediated endocytosis. Conclusion: This study demonstrated the successful application of HINPs as nanocarriers for delivering ICG to CD44-positive cervical cancer, with improved efficacy in NIR fluorescence imaging.
정연수,이산희,임가원,남은지,김성훈,김상운,김희정,현미리,백선미,김재욱,김영태 대한산부인과학회 2014 대한산부인과학회 학술대회 Vol.100 No.-
목적: The aim of this study was to investigate whether Mullerian inhibiting substance (MIS) in combination with calcitriol modulates apoptosis of human ovarian cancer cell lines (SKOV3, OVCAR3, and OVCA433), and to identify the signaling pathway by which MIS mediates apoptosis. 방법: SKOV3, OVCAR3, and OVCA433 cells were exposed to MIS in the presence or absence of calcitriol. Cell viability, proliferation, and apoptosis were evaluated by MTT assay and PI staining. Western blot and RT-PCR assays were used to investigate the signaling pathway. Inhibition of PI3K activation was conducted with chemical inhibitors (LY294002); PD98059 was used to inhibit ERK and SP600125 was employed to inhibit JNK signaling. 결과: All cell lines showed strong specific staining for MISR II. Treatment of ovarian cancer cells with MIS and calcitriol led to dose- and time-dependent inhibition of cell growth and survival. Combination treatment dramatically suppressed cell growth, up-regulated the expression of Bcl-2-associated X protein, down-regulated the expression of Bcl-2 and caspase-3, and increased the proportion of G1 phase fraction and apoptotic cells through the PI3K, ERK and JNK signaling pathways. 결론: These results offer a strong rationale for testing the therapeutic potential of MIS alone or in combination with calcitriol in the treatment of ovarian cancer, which could lead to a much-needed decrease in toxicity compared to currently employed therapeutic agents.
정용욱,이산희,백지흠,남은지,김상운,김재훈,김재욱,김영태 대한부인종양학회 2009 Journal of Gynecologic Oncology Vol.20 No.3
Objective: To evaluate the acute toxicity of rofecoxib during concurrent use with cisplatin-based chemoradiotherapy (CCRT) in patients with cervical cancer. Methods: We evaluated 67 FIGO stage IB2-IVA cervical cancer patients treated with CCRT between June 2002 and July 2004. The study group included patients who received rofecoxib (N=30) and the control group included patients who received CCRT only (N=37). The patients’ medical records were retrospectively reviewed for patient characteristics, toxicity related to CCRT and treatment results. Results: There were no significant differences in toxicity between the two groups. The most common acute grade 3/4 toxicity was neutropenia (13.3% in the study group and 21.6% in the control group). Grade 3/4 late toxicity was observed in 2 (6.6%) patients in the study group and 3 (8.1%) in the control group. There was no treatment-related deaths in either group. Six (20.0%) patients in the study group had treatment failure. In the control group, 6 (16.2%) patients experienced treatment failure. Progression-free and overall survival was 55.8±4.2 and 59.0±2.8 months, respectively, in the study group, and 69.7±4.3 and 71.6±3.6 months, respectively, in the control group. There were no differences in progression-free and overall survival between the 2 groups. Conclusion: Our data indicate that rofecoxib, at a dose of 25 mg twice daily, has acceptable acute toxicity as a radiosensitizer during CCRT. Although rofecoxib was not efficacious as a radiosensitizer in the present study, the benefit of rofecoxib as a radiosensitizer should be further evaluated in a prospective study.